In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cartiva Inc.

Division of Wright Medical Group NV
www.cartiva.net

Latest From Cartiva Inc.

Wright To Pay $435M For Cartiva To Add Synthetic Cartilage Implant

Cartiva's Synthetic Cartilage Implant for treating arthritis at the base of the great toe will instantly be Wright's most profitable product and one of its fastest growing.

Commercial Companies

Market Intel: Orthobiologics Market Well-Positioned For Innovative Reconstruction

Global sales of orthobiologics for musculoskeletal soft tissue replacement and regeneration are predicted to hit $1.4bn by 2021, driven largely by rising numbers of sports injuries requiring treatment, but also by a higher prevalence of osteoarthritis and a need for innovative treatments for musculoskeletal repair. This article offers an in-depth look at the orthobiologics market landscape for cartilage, meniscus and ligament/tendon replacement and regeneration, as well as insight from an orthopedic surgeon. It also analyzes key players in these markets and highlights emerging trends and the greatest barriers for wider adoption of products.

Orthopedics Cellular & Genetic

Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2017

Medtech companies brought in $2.3 billion in financing in Q1 2017, a slight decrease from Q4 2016; device M&A deals totaled $5.8 billion, a sharp decline from the prior quarter, but there were some billion-dollar deals. Q1 diagnostics financings – totaling $1.2 billion (thanks to a $900 million Series B round by cancer diagnostics company Grail) – showed a significant increase over the preceding quarter, as did the Q1 M&As at $700 million versus the previous $87 million.

Medical Device In Vitro Diagnostics

Despite Data Concerns, Panel Recommends First-In-Class Toe Implant

Cartiva, a toe implant to treat osteoarthritis, received a strong recommendation from a panel of FDA experts despite suggestions that the device had not fully proven itself.

Medical Device Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
    • Biomaterials
    • Implantable Devices
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Wright Medical Group NV
  • Senior Management
  • Timothy J Patrick, Pres. & CEO
    Peter J Pizzo, VP, Fin. & CFO
    Robert R Singer, VP, Sales
  • Contact Info
  • Cartiva Inc.
    Phone: (770) 754-3855
    6120 Windward Pkwy., Ste. 220
    Alpharetta, GA
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register